CVRx (Barostim) develops implantable neuromodulation medical devices that deliver baroreflex activation therapy (BAT) to treat cardiovascular conditions, principally heart failure and resistant hypertension.
The company’s Barostim systems are designed to stimulate carotid baroreceptors to modulate autonomic (sympathetic/parasympathetic) activity, supporting improved cardiac function and symptom management within clinical care pathways for cardiovascular disease.
Leadership & Board
Current Number of Employees258
Current LinkedIn Followers21,386
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$50M
Total Amount Raised$50M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$50M
Latest Funding Amount$50M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
CVRx | Barostim had 258 employees as of September 28, 2026. The number of employees decreased by 1 (0.39%) week-over-week.
258Latest Employee Count
1(-0.39%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
CVRx | Barostim had 21,386 followers as of September 28, 2026. The number of followers increased by 108 (0.51%) week-over-week.
21,386Latest Followers Count
108(0.51%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.